Pancreatic Ductal Adenocarcinoma (PDAC)
Conditions
Brief summary
To assess whether EUS (Endoscopic Ultrasound) can serve as a valuable diagnostic tool for identifying PDAC at an early stage in individuals who have recently been diagnosed with diabetes. Purpose: To improve the rates of early detection of pancreatic cancer. Pancreatic ductal adenocarcinoma (PDAC) is a type of cancer that starts in the pancreas, a gland located in your abdomen. It happens when some cells in the pancreas start growing abnormally and form a cancer.
Interventions
PROCEDUREA blood sample for CA 19-9 (cancer detection test)
* A blood sample for CA 19-9 (cancer detection test) levels will be taken at baseline. * Contrast CT abdomen - Pancreas protocol will be done at baseline. * EUS (Endoscopic Ultrasound) under moderate sedation will be done at baseline to you. * If suspicious lesion is found on examination, Fine Needle Aspiration - FNA will be done.
Sponsors
Asian Institute of Gastroenterology, India
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
50 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Age \> 50 years * Patients diagnosed with diabetes based on FBS/ PPBS/ HbA1C * Presence of atleast 1 FBS parameter measured in the past 6-18 months which was not \> 125 mg/dl * END-PDAC score \> 2
Exclusion criteria
* Known or newly detected chronic pancreatitis * Past history of pancreatic cancer * History of steroid use * Contraindications for EUS
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of PDAC at 3 years | 3yrs |
Secondary
| Measure | Time frame |
|---|---|
| • Incidence of PDAC at baseline • Incidence of resectable PDAC at baseline • Incidence of resectable PDAC at 3 years | baseline and 3yrs |
Outcome results
None listed